Back to today’s briefing

Story perspectives

Genflow and Heureka Labs Unite to Transform Drug Discovery

4/14/2025

25 6

Summary

Story summary

Genflow Biosciences, Europe's sole publicly traded longevity firm, has joined forces with Heureka Labs to revolutionize drug discovery through AI. This exciting partnership aims to advance Genflow's flagship gene therapy candidate, GF-1002, while potentially benefiting additional projects. By harnessing AI, they will unlock insights from complex genomic data, paving the way for better therapies and improved patient outcomes.

1 of 1

Story summary

Genflow Biosciences, Europe's sole publicly traded longevity firm, has joined forces with Heureka Labs to revolutionize drug discovery through AI. This exciting partnership aims to advance Genflow's flagship gene therapy candidate, GF-1002, while potentially benefiting additional projects. By harnessing AI, they will unlock insights from complex genomic data, paving the way for better therapies and improved patient outcomes.